Skip to content

Enterprise value at other companies

Incyte logo
IncyteINCY
$15.31B+55.9%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$9.22B-29.3%
UroGen Pharma logo
UroGen PharmaURGN
$962.43M+80.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$958.05M+65.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.79B+318%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s enterprise value?
Tyra Biosciences, Inc. (TYRA) reported enterprise value of $1.98B in Q1 2026.
How has Tyra Biosciences, Inc.'s enterprise value changed year-over-year?
Tyra Biosciences, Inc.'s enterprise value increased by 397.0% year-over-year, from $399.14M to $1.98B.
What is the long-term trend for Tyra Biosciences, Inc.'s enterprise value?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s enterprise value has grown at a 47.2% compound annual growth rate (CAGR), from $283.63M to $1.33B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.